PP_1170x120_10-25-21

Pharmacy Outlook: Stephen Ubl, PhRMA

Pharmacy Outlook: Stephen Ubl, PhRMA

Throughout 2021, lawmakers engaged in a robust debate over ways to lower the cost of prescription drugs. Our industry was at the center of this debate, fighting for reforms that would lower costs at the pharmacy while preserving patient access to life-saving medicines and future innovation. Unfortunately, Congress refused to take a holistic approach that

Drug pricing debate ignores salient facts

Drug pricing debate ignores salient facts

Over the past several months, many Americans have walked into their local pharmacies weighed down by the constant threat of a deadly coronavirus. By the time they walked out, they got a shot in their arm that will help protect them from COVID-19. For many, getting vaccinated offers more than immunity. It provides relief after

Pharmacy Outlook: Stephen Ubl, PhRMA

Pharmacy Outlook: Stephen Ubl, PhRMA

At the start of 2020, our members were focused on continuing their research and development of transformative treatments for the most difficult diseases, such as cell and gene therapies. We planned on making strides on new medicines for chronic diseases like diabetes, heart disease and cancer. And we planned on pushing for policy solutions that

Ending the pandemic will require innovation and access

Ending the pandemic will require innovation and access

Long after the sun goes down, the work of America’s biopharmaceutical companies continues deep into the night. Researchers and scientists labor around the clock, developing new ways to diagnose, treat and cure COVID-19. While they do, so many of the people they’re working to help stare at the ceiling and wonder how they will afford

Making health care work better for patients

Making health care work better for patients

Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. Pharmacists are medication experts. Every day, they get to see the remarkable difference innovative treatments can make in their customers’ lives. But like America’s biopharmaceutical companies, they also know those innovative medicines aren’t nearly as meaningful if they are too

Time to start sharing the Rx savings with patients

Time to start sharing the Rx savings with patients

Every day at America’s community pharmacies, patients pay a bigger and bigger share of the cost for their prescription medications. But two new studies have revealed one of the puzzling reasons why — and how market-based solutions could help ease the strain on America’s patients. Like any complex U.S. industry, the biopharmaceutical sector relies on

Good news in Rx: Treatment options keep growing

Good news in Rx: Treatment options keep growing

When chain drug store customers are waiting in line at the pharmacy, odds are they have at least one thing on their mind: relief for their disease or condition. The good news is that at the start of 2017, America’s chain drug store customers will see more available treatment options than at any other time